Report of the 19th follow-up survey of primary liver cancer in Japan

Hepatology Research

Volumn 46, Issue 5, 2016, Pages 372-390

  Kudo, Masatoshi ^a   Izumi, Namiki ^a   Ichida, Takafumi ^a   Ku, Yonson ^a   Kokudo, Norihiro ^a   Sakamoto, Michiie ^a   Takayama, Tadatoshi ^a   Nakashima, Osamu ^a   Matsui, Osamu ^a   Matsuyama, Yutaka ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Combined hepatocellular and cholangiocarcinoma; Cumulative survival rate; Follow up survey; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ABLATION THERAPY; AGED; ARTERIAL EMBOLIZATION; ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HISTOPATHOLOGY; HUMAN; JAPAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; TUMOR VOLUME;

EID: 84966546678     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12697     Document Type: Article

References (37)

1. Liver Cancer Study Group of Japan. Classiffication of primary liver cancer, 1st English edn. Tokyo, Japan: Kanehara & Co., Ltd., 1997.
2. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, 2nd English edn. Tokyo, Japan: Kanehara & Co., Ltd., 2003.
3. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, 3rd English edn. Tokyo, Japan: Kanehara & Co., Ltd., 2010.
4. Okuda K: The Liver Cancer Study Group of Japan. Primary liver cancers in Japan. Cancer 1980; 45: 2663-9.
5. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1984; 54: 1747-55.
6. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan - Sixth report. Cancer 1987; 60: 1400-11.
7. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989; 19: 98-129.
8. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Ann Surg 1990; 211: 277-87.
9. Tobe T, Kameda H, Okudaira M et al. (Eds). Primary Liver Cancer in Japan. Tokyo, Japan: Springer Japan, 1992.
10. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74: 2772-80.
11. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
12. Ikai I, Itai Y, Okita K et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res 2004; 28: 21-9.
13. Ikai I, Arii S, Kojiro M et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
14. Ikai I, Arii S, Ichid T et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32: 163-72.
15. Ikai I, Arii S, Okazaki M et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37: 676-91.
16. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
17. Ikai I, Takayasu K, Omata M et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41: 884-92.
18. Minagawa M, Ikai I, Matsuyama Y et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan. Ann Surg 2007; 245: 909-22.
19. Eguchi S, Kanematsu T, Arii S et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143: 469-75.
20. Hasegawa K, Makuuchi M, Takayama T et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49: 589-94.
21. Hasegawa K, Makuuchi M, Takayama T et al. Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma: reply. J Hepatol 2009; 50: 1051-6.
22. Takayasu K, Arii S, Ikai I et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010; 194: 830-7.
23. Ikai I, Kudo M, Arii S et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-59.
24. Eguchi S, Kanematsu T, Arii S et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Brit J Surg 2011; 98: 552-7.
25. Higashi T, Hasegawa K, Kokudo N et al. Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatol Res 2011; 41: 1208-15.
26. Takayasu K, Arii S, Kudo M et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886-92.
27. Takayasu K, Arii S, Sakamoto M et al. Clinical implication of hypovascular hepatocellular carcinoma studied in 4, 474 patients with solitary tumour equal or less than 3 cm. Liver Int 2013; 33: 762-70.
28. Hasegawa K, Kokudo N, Makuuchi M et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-9.
29. Nouso K, Miyahara K, Uchida D et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013; 542: 1904-7.
30. Aoki T, Kokudo N, Matsuyama Y et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1, 160 cases from a nationwide survey. Ann Surg 2014; 259: 532-42.
31. Utsunomiya T, Shimada M, Kudo M et al. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to therapeutic impact. Ann Surg 2014; 259: 336-45.
32. Hasegawa K, Makuuchi M, Kokudo N et al. Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: a report of a Japanese nationwide survey. Ann Surg 2014; 259: 166-70.
33. Kitai S, Kudo M, Izumi N et al. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4, 649 cases from a Japanese nationwide survey. Dig Dis 2014; 32: 717-24.
34. Utsunomiya T, Shimada M, Kudo M et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11, 950 patients. Ann Surg 2015; 261: 513-20.
35. Sakamoto Y, Kokudo N, Matsuyama Y et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016; 122: 61-70.
36. Kudo M, Kubo S, Takayasu K et al. Response evaluation criteria in cancer of the liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res 2010; 40: 686-92.
37. Kudo M, Ueshima K, Kubo S et al. Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version). Hepatol Res 2016; 46: 3-9.